Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

• ClinicalTrials.gov Identifier: NCT03164616
• Recruitment Status: Active, not recruiting
• First Posted: May 23, 2017
• Results First Posted: April 7, 2022
• Last Update Posted: March 5, 2024
• Sponsor: AstraZeneca
• Information provided by (Responsible Party): AstraZeneca

Study Description

Brief Summary:

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Condition or disease	Intervention/treatment	Phase
Non Small Cell Lung Cancer NSCLC	Drug: Durvalumab; Drug: Tremelimumab; Drug: Abraxane + carboplatin; Drug: Gemcitabine + cisplatin; Drug: Gemcitabine + carboplatin; Drug: Pemetrexed + carboplatin; Drug: Pemetrexed + cisplatin	Phase 3

Detailed Description:

Adult patients with a histologically or cytologically documented metastatic NSCLC, with tumors that lack activating EGFR mutations and ALK fusions, are eligible for enrollment. Patients will be randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab combination therapy + SoC chemotherapy, durvalumab monotherapy + SoC chemotherapy, or SoC chemotherapy alone. Tumor evaluation scans will be performed until objective disease progression as efficacy assessment. All patients will be followed for survival until the end of the study. An independent data monitoring committee (IDMC) composed of independent experts will be convened to confirm the safety and tolerability of the proposed dose and schedule.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1186 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
• Actual Study Start Date: June 1, 2017
• Actual Primary Completion Date: March 12, 2021
• Estimated Study Completion Date: May 28, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment Arm 1; durvalumab + tremelimumab combination therapy + SoC chemotherapy	Drug: Durvalumab; IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria; Drug: Tremelimumab; IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.; Drug: Abraxane + carboplatin; Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Gemcitabine + cisplatin; Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Gemcitabine + carboplatin; Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Pemetrexed + carboplatin; Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.; Drug: Pemetrexed + cisplatin; Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.
Experimental: Treatment Arm 2; durvalumab monotherapy + SoC chemotherapy	Drug: Durvalumab; IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria; Drug: Abraxane + carboplatin; Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Gemcitabine + cisplatin; Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Gemcitabine + carboplatin; Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Pemetrexed + carboplatin; Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.; Drug: Pemetrexed + cisplatin; Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.
Active Comparator: Treatment Arm 3; SoC chemotherapy alone	Drug: Abraxane + carboplatin; Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Gemcitabine + cisplatin; Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Gemcitabine + carboplatin; Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).; Drug: Pemetrexed + carboplatin; Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.; Drug: Pemetrexed + cisplatin; Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance [i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)] until objective disease progression.

Outcome Measures

Primary Outcome Measures :

1. Progression-Free Survival (PFS); D + SoC Compared With SoC Alone [ Time Frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months). ]
   PFS (per RECIST version 1.1 [RECIST 1.1] using Blinded Independent Central Review [BICR] assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique. The final analysis of PFS in the global cohort was pre-specified after approximately 497 BICR PFS events occurred across the D + SoC and SoC alone treatment arms (75% maturity).
2. Overall Survival (OS); D + SoC Compared With SoC Alone [ Time Frame: From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months). ]
   OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. The final analysis of OS in the global cohort was pre-specified after approximately 532 OS events occurred across the D + SoC and SoC alone treatment arms (80% maturity).

Secondary Outcome Measures :

1. PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC [ Time Frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months. ]
   PFS (per RECIST 1.1 using BICR assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.
2. OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC [ Time Frame: From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months). ]
   OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
3. Objective Response Rate (ORR) [ Time Frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months). ]
   ORR (per RECIST 1.1 using BICR assessments) was defined as the percentage of patients with at least one visit response of complete response (CR) or partial response (PR). Results are presented for the pre-specified ORR analysis using unconfirmed responses based on BICR.
4. Best Objective Response (BoR) [ Time Frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months). ]
   The BoR was calculated based on the overall visit responses from each RECIST 1.1 assessment. BOR was defined as the best response a patient had following randomization, but prior to starting any subsequent cancer therapy and up to and including RECIST 1.1 progression or the last evaluable assessment in the absence of RECIST 1.1 progression, as determined by BICR. Categorization of BoR was based on RECIST using the following 'response' categories: CR and PR and the following 'non-response' categories: stable disease (SD) ≥6 weeks, progression (ie, PD) and not evaluable (NE). Results are presented for number (%) of patients in each specified category.
5. Duration of Response (DoR) [ Time Frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months). ]
   DoR (per RECIST 1.1 using BICR assessments) was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression. The end of response coincided with the date of progression or death from any cause used for the RECIST 1.1 PFS endpoint. The time of the initial response was defined as the latest of the dates contributing towards the first visit of PR or CR. Results are presented for the pre-specified DoR analysis using unconfirmed responses based on BICR.
6. Time From Randomization to Second Progression (PFS2) [ Time Frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months). ]
   PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS) or death. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of: objective radiological imaging, symptomatic progression or death.
7. Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations [ Time Frame: Samples were collected post-dose on Day 1 (Week 0), pre-dose on Weeks 3 and 12 and at follow-up (3 months after the last valid dose). Assessed at the global cohort DCO of 12 March 2021. ]
   To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.
8. PK of Tremelimumab; Peak and Trough Serum Concentrations [ Time Frame: Samples were collected post-dose on Day 1 (Week 0), pre-dose on Weeks 3 and 12 and at follow-up (3 months after the last valid dose). Assessed at the global cohort DCO of 12 March 2021. ]
   To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.
9. Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab [ Time Frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of study treatment (ie, durvalumab). ]
   Blood samples were collected at pre-specified timepoints and number of patients who developed detectable ADAs against durvalumab was determined. ADA prevalence is defined as percentage of patients with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as either treatment-induced ADA or treatment-boosted ADA. ADA incidence is percentage of patients who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted by ≥4-fold during the study period. Persistently positive is defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks (112 days) between the first and last positive, or an ADA positive result at the last available assessment. Transiently positive is defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of neutralizing antibody (nAb) was tested for all ADA positive samples.
10. Number of Patients With ADA Response to Tremelimumab [ Time Frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of study treatment (ie, tremelimumab). ]
    Blood samples were collected at pre-specified timepoints and number of patients who developed detectable ADAs against tremelimumab was determined. ADA prevalence is defined as percentage of patients with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as either treatment-induced ADA or treatment-boosted ADA. ADA incidence is percentage of patients who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted by ≥4-fold during the study period. Persistently positive is defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks (112 days) between the first and last positive, or an ADA positive result at the last available assessment. Transiently positive is defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of nAb was tested for all ADA positive samples.
11. Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) [ Time Frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever came first). Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months). ]
    The EORTC QLQ-Core 30 version 3 (QLQ-C30 v3) was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration was defined as time from randomization until the date of first clinically meaningful deterioration that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.
12. Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13) [ Time Frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever came first). Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months). ]
    The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and treatment-related symptoms from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration was defined as time from randomization until the date of first clinically meaningful deterioration that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 130 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

For inclusion in the study, patients should fulfill the following criteria:

1. Aged at least 18 years.
2. Histologically or cytologically documented Stage IV NSCLC.
3. Confirmed tumor PD-L1 status prior to randomization.
4. Patients must have tumors that lack activating EGFR mutations and ALK fusions.
5. No prior chemotherapy or any other systemic therapy for metastatic NSCLC.
6. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. No prior exposure to immunemediated therapy, excluding therapeutic anticancer vaccines.

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant.
2. Active or prior documented autoimmune or inflammatory disorders.
3. Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids.
4. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.

Contacts and Locations

Locations

United States, Arizona

Research Site

Phoenix, Arizona, United States, 85054

United States, California

Research Site

Bakersfield, California, United States, 93309

Research Site

Santa Monica, California, United States, 90404

United States, Florida

Research Site

Fort Myers, Florida, United States, 33901

Research Site

Jacksonville, Florida, United States, 32224

Research Site

Saint Petersburg, Florida, United States, 33705

Research Site

West Palm Beach, Florida, United States, 33401

United States, Kentucky

Research Site

Louisville, Kentucky, United States, 40202

United States, Missouri

Research Site

Kansas City, Missouri, United States, 64132

United States, Ohio

Research Site

Canton, Ohio, United States, 44710

United States, Pennsylvania

Research Site

Pittsburgh, Pennsylvania, United States, 15212

United States, Tennessee

Research Site

Chattanooga, Tennessee, United States, 37404

Research Site

Nashville, Tennessee, United States, 37203

United States, Texas

Research Site

Fort Worth, Texas, United States, 76104

Research Site

Houston, Texas, United States, 77090

United States, Virginia

Research Site

Richmond, Virginia, United States, 23298

Brazil

Research Site

Barretos, Brazil, 14784-400

Research Site

Belo Horizonte, Brazil, 30380-472

Research Site

Curitiba, Brazil, 81520-060

Research Site

Porto Alegre, Brazil, 90035-003

Research Site

Porto Alegre, Brazil, 90610-000

Research Site

Porto Alegre, Brazil, 91350-200

Research Site

Ribeirao Preto, Brazil, 14015-140

Research Site

Rio de Janeiro, Brazil, 20231-050

Research Site

Santo Andre, Brazil, 09080-110

Research Site

Santo André, Brazil, 09060-650

Research Site

Sao Paulo, Brazil, 01209-000

Research Site

São José do Rio Preto, Brazil, 15090-000

Research Site

São Paulo, Brazil, 01246-000

Research Site

São Paulo, Brazil, 03102-002

Bulgaria

Research Site

Plovdiv, Bulgaria, 4000

Research Site

Plovdiv, Bulgaria, 4004

Research Site

Sofia, Bulgaria, 1330

Research Site

Sofia, Bulgaria, 1431

Research Site

Sofia, Bulgaria, 1618

Research Site

Sofia, Bulgaria, 1784

Research Site

Varna, Bulgaria, 9010

China

Research Site

Beijing, China, 100021

Research Site

Beijing, China, 100142

Research Site

Changchun, China, 130012

Research Site

Changsha, China, 410013

Research Site

Fuzhou, China, 350014

Research Site

Guangzhou, China, 510080

Research Site

Hangzhou, China, 310022

Research Site

Harbin, China, 150081

Research Site

Hefei, China, 230601

Research Site

Kunming, China, CN-650034

Research Site

Linyi, China, 276000

Research Site

Liuzhou, China, 545006

Research Site

Nanjing, China, 210009

Research Site

Qingdao, China, 110016

Research Site

Shanghai, China, 200030

Research Site

Shanghai, China, 200032

Research Site

Shanghai, China, 200080

Research Site

Shantou, China, 515041

Research Site

Wuhan, China, 430022

Research Site

Wuhan, China, 430079

Research Site

Xining, China, 810001

Research Site

Yangzhou, China, 225001

Research Site

Zhanjiang, China, 524001

Research Site

Zhengzhou, China, 450008

Research Site

Zhengzhou, China, 450052

Germany

Research Site

Berlin, Germany, 13125

Research Site

Essen, Germany, 45122

Research Site

Freiburg, Germany, 79106

Research Site

Gauting, Germany, 82131

Research Site

Hamburg, Germany, 20251

Research Site

Hamburg, Germany, 21075

Research Site

Heidelberg, Germany, 69126

Research Site

Immenhausen, Germany, 34376

Research Site

Mainz, Germany, 55131

Research Site

Oldenburg, Germany, 26121

Research Site

Würzburg, Germany, 97067

Hong Kong

Research Site

Shatin, Hong Kong, 00000

Hungary

Research Site

Budapest, Hungary, 1083

Research Site

Budapest, Hungary, 1121

Research Site

Kecskemét, Hungary, 6000

Research Site

Miskolc, Hungary, 3529

Research Site

Törökbálint, Hungary, 2045

Japan

Research Site

Bunkyo-ku, Japan, 113-8603

Research Site

Chuo-ku, Japan, 104-0045

Research Site

Fukuoka-shi, Japan, 812-8582

Research Site

Hiroshima-shi, Japan, 730-0011

Research Site

Iwakuni-shi, Japan, 740-8510

Research Site

Kanazawa, Japan, 920-8641

Research Site

Kashiwa, Japan, 227-8577

Research Site

Koto-ku, Japan, 135-8550

Research Site

Kurume-shi, Japan, 830-0011

Research Site

Matsuyama-shi, Japan, 790-0007

Research Site

Okayama-shi, Japan, 700-8558

Research Site

Okayama-shi, Japan, 700-8607

Research Site

Osakasayama, Japan, 589-8511

Research Site

Sapporo-shi, Japan, 003-0804

Research Site

Sunto-gun, Japan, 411-8777

Research Site

Toyoake-shi, Japan, 470-1101

Research Site

Ube-shi, Japan, 755-0241

Research Site

Yokohama-shi, Japan, 236-0004

Research Site

Yokohama-shi, Japan, 241-8515

Korea, Republic of

Research Site

Busan, Korea, Republic of, 47392

Research Site

Chungcheongbuk-do, Korea, Republic of, 28644

Research Site

Daegu, Korea, Republic of, 42415

Research Site

Incheon, Korea, Republic of, 21565

Research Site

Seongnam-si, Korea, Republic of, 13620

Research Site

Seoul, Korea, Republic of, 05505

Research Site

Seoul, Korea, Republic of, 06591

Research Site

Seoul, Korea, Republic of, 120-752

Research Site

Seoul, Korea, Republic of, 6351

Research Site

Ulsan, Korea, Republic of, 44033

Mexico

Research Site

Aguascalientes, Mexico, 20230

Research Site

Cuautitlan Izcalli, Mexico, 54769

Research Site

Guadalajara, Mexico, 44280

Research Site

Mexico City, Mexico, 0 3100

Research Site

Mexico, Mexico, 14080

Research Site

Monterrey, Mexico, 64060

Research Site

Monterrey, Mexico, 64460

Research Site

México, Mexico, 04739

Research Site

Tuxtla, Mexico, 29030

Peru

Research Site

Arequipa, Peru, AREQUIPA01

Research Site

Lima, Peru, L27

Research Site

Lima, Peru, LIMA 29

Research Site

Lima, Peru, LIMA 34

Research Site

Lima, Peru, LIMA 41

Research Site

San Isidro, Peru, 27

Poland

Research Site

Olsztyn, Poland, 10-357

Research Site

Tomaszów Mazowiecki, Poland, 97-200

Research Site

Warszawa, Poland, 02-781

Research Site

Wodzisław Śląski, Poland, 44-300

Russian Federation

Research Site

Moscow, Russian Federation, 105229

Research Site

Moscow, Russian Federation, 115280

Research Site

Moscow, Russian Federation, 115478

Research Site

Moscow, Russian Federation, 125367

Research Site

Omsk, Russian Federation, 644013

Research Site

Saint Petersburg, Russian Federation, 195271

Research Site

Saint-Petersburg, Russian Federation, 194291

Research Site

Sankt-Peterburg, Russian Federation, 196603

Research Site

St. Petersburg, Russian Federation, 197758

South Africa

Research Site

Durban, South Africa, 4091

Research Site

Johannesburg, South Africa, 0001

Research Site

Kraaifontein, South Africa, 7570

Research Site

Parktown, South Africa, 2193

Research Site

Pretoria, South Africa, 0001

Research Site

Rondebosch, South Africa, 7700

Research Site

Vereeniging, South Africa, 1930

Taiwan

Research Site

Changhua City, Taiwan, 50006

Research Site

Kaohsiung City, Taiwan, 83301

Research Site

Kaohsiung, Taiwan, 82445

Research Site

Taichung, Taiwan, 40447

Research Site

Taichung, Taiwan, 40705

Research Site

Tainan, Taiwan, 70403

Research Site

Taipei, Taiwan, 10002

Research Site

Taipei, Taiwan, 112

Research Site

Taipei, Taiwan, 235

Research Site

Tao-Yuan, Taiwan, 333

Thailand

Research Site

Bangkok, Thailand, 10210

Research Site

Bangkok, Thailand, 10330

Research Site

Bangkok, Thailand, 10400

Research Site

Muang, Thailand, 50200

Research Site

Songkhla, Thailand, 90110

Ukraine

Research Site

Dnipro, Ukraine, 49102

Research Site

Ivano-Frankivsk, Ukraine, 76018

Research Site

Kirovohrad, Ukraine, 25006

Research Site

Kyiv, Ukraine, 03022

Research Site

Kyiv, Ukraine, 03115

Research Site

Lviv, Ukraine, 79031

Research Site

Odesa, Ukraine, 65055

Research Site

Sumy, Ukraine, 40022

Research Site

Vinnytsia, Ukraine, 21029

Research Site

Zaporizhzhia, Ukraine, 69040

United Kingdom

Research Site

Leicester, United Kingdom, LE1 5WW

Research Site

London, United Kingdom, EC1M 6BQ

Research Site

London, United Kingdom, NW1 2PG

Research Site

London, United Kingdom, W6 8RF

Research Site

Manchester, United Kingdom, M20 4BX

Vietnam

Research Site

Hanoi, Vietnam, 100000

Research Site

Ho Chi Minh, Vietnam, 700000

Sponsors and Collaborators

AstraZeneca

Investigators

• Study Director: Xiaojin Shi, M.D., MSc; One MedImmune Way, Gaithersburg, Maryland 20878, United States

  Study Documents (Full-Text)

Documents provided by AstraZeneca:

Study Protocol  [PDF] July 9, 2021

Statistical Analysis Plan  [PDF] February 25, 2021

More Information

Additional Information:

Related Info 

Related Info 

Related Info 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3.

• Responsible Party: AstraZeneca
• ClinicalTrials.gov Identifier: NCT03164616
• Other Study ID Numbers: D419MC00004; 2017-000920-81 ( EudraCT Number )
• First Posted: May 23, 2017
• Results First Posted: April 7, 2022
• Last Update Posted: March 5, 2024
• Last Verified: February 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP)
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
• Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
• URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AstraZeneca:

NSCLC; Programmed cell death ligand 1 (PD-L1); Durvalumab; Tremelimumab; Progression-free survival (PFS); Overall survival (OS)

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Cisplatin; Carboplatin; Gemcitabine; Pemetrexed; Durvalumab; Albumin-Bound Paclitaxel; Tremelimumab; Antineoplastic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors; Antineoplastic Agents, Immunological